Several microtubule targeting agents are capable of inducing CYP3A4 via activation of the pregnane X receptor (PXR; NR1I2).
Objective:
To evaluate the CYP3A4 induction potential of vinblastine both clinically and in vitro and determine the involvement of the nuclear receptors NR1I2 and the constitutive androstane receptor (NR1I3).
Methods:
Midazolam pharmacokinetics were evaluated in 6 patients who were enrolled in a Phase 1/2 study of infusional vinblastine given in combination with the ABCB1 (P-glycoprotein) antagonist valspodar (PSC 833) and received the CYP3A4 phenotyping probo midazolam on more than 1 occasion. Genotyping was conducted in CYP3A4, CYP3A5, and ABCB1 to rule out potential pharmacogenetic influences. Clinical data were followed-up by Western blotting and reporter assays in HepG2 and NIH3T3 cells treated with vinbfastine over a dose range of 150-4800 ng/mL for 48 hours.
Results:
In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test). No obvious effect of polymorphisms in CYP3A4, CYP3A5, and ABCB1 on midazolam clearance was observed. In vitro, vinblastine induced CYP3A4 protein. Furthermore, cell-based reporter gene assays using transiently transfected HepG2 and NIH3T3 cells indicated that vinblastine (150-4800 ng/mL) weakly activated human and mouse full-length NR1I2, but had no influence on NR1I3.
Conclusions:
Collectively, these findings suggest that vinblastine is able to induce CYP3A4, at least in part, via an NR1I2-dependent mechanism, and thus has the potential to facilitate its own elimination and cause interactions with other CYP3A4 substrates.
RowinskyEK, TolcherAW. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins, 2004.
2.
RahmaniR, ZhouXJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv1993; 17:269–81.
3.
RatainMJ, VogelzangNJ, SinkuleJA. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther1987; 41:61–7.
4.
BaumhakelM, KaselD, Rao-SchymanskiRA. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther2001; 39:517–28.
5.
BohmeA, GanserA, HoelzerD. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol1995; 71:311–2.
6.
FedeliL, ColozzaM, BoschettiE. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer1989; 64:1805–11.
7.
VillikkaK, KivistoKT, MaenpaaH, JoensuuH, NeuvonenPJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther1999; 66:589–93.
8.
YaoD, DingS, BurchellB, WolfCR, FriedbergT. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther2000; 294:387–95.
Zhou-PanXR, SereeE, ZhouXJ. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res1993; 53:5121–6.
11.
ZhouXJ, MartinM, PlacidiM, CanoJP, RahmaniR. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur J Drug Metab Pharmacokinet1990; 15:323–32.
12.
KostrubskyVE, LewisLD, StromSC. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys1998; 355:131–6.
13.
ManiS, HuangH, SundarababuS. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res2005; 11:6359–69.
14.
SynoldTW, DussaultI, FormanBM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med2001; 7:584–90.
15.
KliewerSA, GoodwinB, WillsonTM. The nuclear pregnane X receptor. a key regulator of xenobiotic metabolism. Endocr Rev2002; 23:687–702.
16.
BatesSE, BakkeS, KangM. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res2004; 10:4724–33.
17.
FischerV, Rodriguez-GasconA, HeitzF. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos1998; 26:802–11.
18.
LepperER, HicksJK, VerweijJ, ZhaiS, FiggWD, SparreboomA. Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci2004; 806:305–10.
19.
LepperER, BakerSD, PermenterM. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res2005; 11:7398–404.
20.
LehmannJM, McKeeDD, WatsonMA, WillsonTM, MooreJT, KliewerSA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest1998; 102:1016–23.
21.
ZhangJ, KuehlP, GreenED. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics2001; 11:555–72.
22.
LambaV, YasudaK, LambaJK. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol2004; 199:251–65.
23.
KawaharaI, KatoY, SuzukiH. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimemylemylaminccarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos2000; 28:1238–43.
24.
KimRB, WandelC, LeakeB. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res1999; 16:408–14.
25.
KurnikD, WoodAJ, WilkinsonGR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther2006; 80:228–34.
26.
HarmsenS, MeijermanI, FebusCL, Maas-BakkerRF, BeijnenJH, SchellensJH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol2009; 66:765–71.
27.
GoodwinB, HodgsonE, D'CostaDJ, RobertsonGR, LiddleC. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol2002; 62:359–65.
28.
DrocourtL, OurlinJC, PascussiJM, MaurelP, VilaremMJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem2002; 277:25125–32.
29.
MakishimaM, LuTT, XieW. Vitamin D receptor as an intestinal bile acid sensor. Science2002; 296:1313–6.
30.
Schmiedlin-RenP, ThummelKE, FisherJM, PaineMF, LownKS, WatkinsPB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of lalpha,25-dihydroxyvitamin D3. Mol Pharmacol1997; 51:741–54.
31.
ThummelKE, BrimerC, YasudaK. Transcriptional control of intestinal cytochrome P-4503A by lalpha,25-dihydroxy vitamin D3. Mol Pharmacol2001; 60:1399–406.
32.
PascussiJM, DrocourtL, Gerbal-ChaloinS, FabreJM, MaurelP, VilaremMJ. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem2001; 268:6346–58.
33.
MulateroC, McClarenBR, MasonM, OliverRT, GallagherCJ. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma. Br J Cancer2000; 83:1612–6.
34.
TeunissenMW, WillemsePH, SleijferDT, SluiterWJ, BreimerDD. Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment. Cancer Chemother Pharmacol1984; 13:181–5.
35.
EngelG, HofmannU, HeidemannH, CosmeJ, EichelbaumM. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther1996; 59:613–23.
36.
HarrisJW, RahmanA, KimBR, GuengerichFP, CollinsJM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res1994; 54:4026–35.
37.
RahmanA, KorzekwaKR, GroganJ, GonzalezFJ, HarrisJW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res1994; 54:5543–6.
